Objectif ExtruLub is an innovative, disruptive extrusion technology applicable across a range of medical polymer resins, which has the ability to change the surface of a catheter without affecting core device properties. The technology sits in the component sub-supply global market with an initial value of €564mn applicable across all catheter markets (combined value of $42.5bn globally by 2020). From a functional perspective, ExtruLub has the ability to reduce surface friction, generate protective antimicrobial & anti-thrombogenic surfaces & deliver site specific drugs all whilst reducing catheter profile. This enhancement of catheter function assists in safeguarding patient safety & will command genuine product differentiation for the original equipment manufacturer (OEM) of the end device, enabling them to gain market share.From an economic perspective it facilitates a change from lean to batch manufacturing realising cost containment for the target customer.Taking the cardiology sector as an example, an independent study demonstrated ExtruLub would reduce costs for the OEM (eg Boston Scientific, Medtronic etc.) by 51% realising savings of ca. €3mn p.a in one product. In the urology sector, the measured impact showed increased gross margins of ca.13% on one product line alone enabling €21.5 mn p.a. savings for potential customers like Hollister, Coloplast etc. DiaNia Technologies ambition is to grow into a world leading, international technology company, realising market share through disruptive technologies.Our initial goal is to replace current ExtruLub alternatives attaining a 30% market share with the friction product, equating to €170mn in full production.Harnessing advanced polymer chemistry through materials science and engineering has the potential to realise €23.3mn in revenue & 15 new, highly skilled jobs within the first 4 years through a business model preferred by OEMs.This disruptive technology is the key to advancing the next generation of medical devices. Champ scientifique engineering and technologymechanical engineeringmanufacturing engineeringmedical and health sciencesclinical medicinesurgerymedical and health sciencesclinical medicineurologynatural scienceschemical sciencespolymer sciencessocial scienceseconomics and businessbusiness and managementbusiness models Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Thème(s) NMP-25-2015-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs Appel à propositions H2020-SMEInst-2014-2015 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2015 Régime de financement SME-1 - SME instrument phase 1 Coordinateur DIANIA TECHNOLOGIES LIMITED Contribution nette de l'UE € 50 000,00 Adresse UNIT 120 NUIG BUSINESS INNOVATION CENTRE UPPER NEWCASTLE H91 Y682 Galway Irlande Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Ireland Northern and Western West Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00